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Background: The identification of very small subsets of predictive variables is an important topic that has not often
been considered in the literature. In order to discover highly predictive yet compact gene set classifiers from whole
genome expression data, a non-parametric, iterative algorithm, Splitting Random Forest (SRF), was developed to
robustly identify genes that distinguish between molecular subtypes. The goal is to improve the prediction accuracy
while considering sparsity.
Results: The optimal SRF 50 run (SRF50) gene classifiers for glioblastoma (GB), breast (BC) and ovarian cancer (OC)
subtypes had overall prediction rates comparable to those from published datasets upon validation (80.1%-91.7%).
The SRF50 sets outperformed other methods by identifying compact gene sets needed for distinguishing between
tested cancer subtypes (10–200 fold fewer genes than ANOVA or published gene sets). The SRF50 sets achieved
superior and robust overall and subtype prediction accuracies when compared with single random forest (RF) and
the Top 50 ANOVA results (80.1% vs 77.8% for GB; 84.0% vs 74.1% for BC; 89.8% vs 88.9% for OC in SRF50 vs single
RF comparison; 80.1% vs 77.2% for GB; 84.0% vs 82.7% for BC; 89.8% vs 87.0% for OC in SRF50 vs Top 50 ANOVA
comparison). There was significant overlap between SRF50 and published gene sets, showing that SRF identifies the
relevant sub-sets of important gene lists. Through Ingenuity Pathway Analysis (IPA), the overlap in “hub” genes
between the SRF50 and published genes sets were RB1, PIK3R1, PDGFBB and ERK1/2 for GB; ESR1, MYC, NFkB and
ERK1/2 for BC; and Akt, FN1, NFkB, PDGFBB and ERK1/2 for OC.
Conclusions: The SRF approach is an effective driver of biomarker discovery research that reduces the number of
genes needed for robust classification, dissects complex, high dimensional “omic” data and provides novel insights
into the cellular mechanisms that define cancer subtypes.
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An important challenge confronting researchers lies in ana-
lyzing large scale high-throughput “omic” datasets and
interpreting results in a biologically meaningful way. Al-
though identifying gene sets that distinguish tumor com-
pared to normal tissue has become routine, it is more
challenging to provide compact gene sets that define histo-
logical subtypes of cancers or predict outcome and/or* Correspondence: jsb42@case.edu
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reproduction in any medium, provided the ortreatment response. In addition, because sample sizes (n)
are generally very small as compared to the dimensionality
of the “omic” data being analyzed (i.e. “big p, small n phe-
nomenom”), overfitting of the data and false positive results
have to be carefully considered. Powerful statistical methods
are in great need to rigorously validate sub sets of accurate
predictors across independently collected blinded samples
from different populations or data sets before these predic-
tors could be used in clinical care [1].
As the state-of-the-art data mining techniques can fall
short of being able to extract the compact gene sets from
high dimensional data, feature selection techniques have
been developed to prioritize a compact subset of the ori-
ginal features according to a specific criterion withouttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are classified into three categories: filter, wrapper and em-
bedded, depending on how and when the utility of selected
features is assessed [2]. Filter methods select features as a
pre-processing step and involve no learning. These meth-
ods are not efficient because they treat biomarkers inde-
pendently and ignore the interactions among them.
Wrapper methods need a predetermined learning algo-
rithm as a black box to score the selected feature subsets;
while these methods account for gene interactions, they
face the problems of over fitting and high computational
complexity. Embedded methods build the search for an
optimal subset of features in the combined space of feature
subsets and hypotheses and show superior performance
while taking into consideration the interactions of the
genes and being less computationally intensive[3]. Linear
classifiers (which fall in the embedded class), such as the
least absolute shrinkage and selection operator (LASSO)
[4], simultaneously produce an accurate and sparse model
because of the regularization resulting from its L1 penalty
(L1 regularization penalizes the weight vector for its L1-
norm, i.e. the sum of the absolute values of the weights.
However, the LASSO has several limitations one of which
is that the number of selected variables is limited by the
number of observations (n), a considerable limitation to
finding compact gene sets [5].
Considering the above advantages and disadvantages of
current analysis methods, new robust analysis methods are
needed to take into account the inherent variability of indi-
vidual tumors and to permit identification of genes that
dominate differences between known tumor subtypes. Mo-
lecular stratification of tumors and/or individuals that
reveals the activation state of specific biological pathways
could allow for improvements in the diagnosis and treat-
ment of cancer. The ensemble-based feature selection
method, Random Forest (RF) [6], allows for relatively few
hyperparameters, ease of identification of variable interac-
tions- as many phenotype groups as necessary- and is
robust to missing values and outliers. Hence, an extended
algorithm, Splitting Random Forest (SRF), which extends
the baseline single RF model, was developed. The SRF algo-
rithm embeds a random splitting test-train technique into
the standard RF algorithm, allowing for identification of a
small set of genes that distinguish between groups while
preserving robust classification power to accurately distin-
guish between tumor subtypes. SRF offers a minimal re-
quirement of human input, robust predictive performance,
and low computational cost.
Methods
Algorithm
The SRF approach is an interactive, non-parametric, deci-
sion tree-based classification statistical method built on an
ensemble of standard un-pruned classification andregression trees (CART) utilizing all information on all
genes[7] [8] (i.e. a “forest” or the Random Forest (RF)
method) in order to identify the optimal tree. The individ-
ual decision trees are generated via bootstrap samples of
the original data which is used as the “training” set from
which to grow the tree. Part of the original data is not
sampled and is used as a “testing” set for the tree; this
group of data is called the “out of the bag” (OOB) samples.
The OOB samples‘error rate is calculated based on the
number of trees in the forest and this rate is generated for
each gene to gene sub-cluster. The smaller the OOB error
rate, the better the classifier. Class prediction is made by
polarity voting for classification for one of the subtype
groupings and variables for this classification are selected
based on their variable importance values (VIM).
Let β
tð Þ
be the out-of-bag sample for a tree t i ¼ 1 . . .ntreeð Þ,
RF employs the following steps to calculate the importance
value zxj for the variable xj in the tree t [9]:
(a) Classify the OOB samples from the tree and record
the number of the correctly predicted classes, denoted as:
Noriginal;xj ¼
P











tð Þ ¼ f tð Þ Xið Þ is the predicted classes for observa-
tion i before permuting the values of variablexj across all
samples, where Xi ¼ xi;1; . . . ; xi;j1; xi;j; xi;jþ1; . . . ; xi;p
 
.
(b) Randomly permute the values of the predictor vari-
able xj across all samples with respect to Y. Rerun the
analysis described in step (a), using the permuted vari-
able,xj , together with the remaining non-permuted pre-
dictor variables, to predict the response for the OOB
observations. The recorded number is denoted as:
Npermuted;xj ¼
P











tð Þ ¼ f tð Þ Xi;πj
 
is the predicted classes for obser-
vation i after randomly permuting the values of variable xj,
where Xi;πj ¼ xi;1; . . . ; xi;j1; xπj ið Þ;j; xi;jþ1; . . . ; xi;p
 
. For
the vector of p values associated with the observation i,
only the value for the xj variable is the randomly permu-
tated value and all other p 1 values for the p 1 vari-
ables remain unchanged.
(c) Calculate the difference of the two counts, denoted
as:
Noriginal;xj  Npermuted;xj ð3Þ
It will decrease substantially if the original variable xj
is associated with the response Y. By definition, this
value is 0 if variable xj is not in tree t.
Figure 1 Flowchart of the Splitting Random Forest (SRF)
Algorithm.
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This algorithm employs the non scaled VIM, which
means the VIM value isn’t divided by the standard error
(SE) of the VIM, denoted as:
scaledVIM ¼ VIMSE VIMð Þ ð5Þ
The non-scaled variable importance measurement
(VIM) for regression was adopted here as it has been
reported that scaled variable importance measurement
was dependent on forest size and predictor correlation.
[9-11]. After each iteration, variables with the lowest im-
portance values are removed and a new forest is gener-
ated using the remaining variables. Individual trees
provide the user with clear information about hierarchy
and relationships between factors; genes at the top of the
tree are the most important and each connection within
the tree links various combinations of genes together.
SRF builds upon the RF algorithm by providing an it-
erative sampling of the data to investigate a wide land-
scape of solutions in order to find the one that optimally
distinguishes between cancer subtypes rather than having
to use predefined cut off values of variable importance.
SRF employs four steps as follows (Figure 1):
Step 1: Starting with a high-throughput dataset, the
time (X) is set as the total number of times that the data
use randomly split into training and testing datatests. RF
is then run on the training datasets. For each run, the
original samples N are split into equal halves. One half
becomes the training dataset (N1=N/2) and the other
becomes the testing dataset (N2=N/2) for each
iteration.
Step 2: Based on the training dataset for each iteration,
the RF variable selection package from R, varSelRF [12]
is then used to identify the optimal subset of genes (G)
out of the total genes (T) with the minimum OOB error.
The number of optimal genes, G, could vary between dif-
ferent iterations. In total, X sets of optimal genes are
generated according to varSelRF algorithm.
Step 3: For each iteration, the gene set (G) is then used
as a classifier to make class predictions on the matching
testing dataset and the overall prediction accuracy of the
classifications is calculated based on the true classes of
the testing data, which is the ratio between the number
of true positives across all subtypes and the total sample.
A set of X prediction accuracies are generated.
Step 4: Finally, the maximum overall prediction accur-
acy is selected based on the maximum value from all X
prediction accuracies and the gene set associated withthis maximal prediction accuracy is extracted as the opti-
mal set that distinguishes between cancer subtypes.
X was set at 50, 100 or 500 runs in order to find the
optimal run time in terms of computation cost, predic-
tion accuracy and the number of selected predictors. By
embedding the splitting in the RF algorithm, the risk of
overfitting is minimized. As SRF is a modified extension
of the varSelRF method, we utilize the default parameter
settings for robust performance. The parameters ntree
and nodesize were set at 5000 and 1, respectively, as
these values have been shown to be robust. The default,
fraction. dropped= 0.2 allows for relatively fast computa-
tional time, which is in coherent with the “aggressive
variable selection” approach[11]. Since the SRF algorithm
applies a test-train technique upon the varSelRF algo-
rithm, computational time is just a linear rate of that of
varSelRF according to how many splits are utilized. R
and Bioconductor [13,14] were used for all data manage-
ment and statistical analysis. R code for the SRF algo-
rithm is available at http://epbiwww.case.edu/SRF.
Data sets
Three publicly available datasets were used: glioblastoma,
breast cancer and ovarian cancer (details are described
below). The original normalized values, without further
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evaluation of SRF so as to effectively compare them with
the intrinsic gene lists as identified in the publications
for these cancers.
Glioblastoma (GB) datasets
Publically available data from The Cancer Genome Atlas
(TCGA) project as described in Verhaak et al. [15], was
used for analysis, including whole-genome gene expression
data on 173 individuals. Individuals were divided into the
following four known GB gene expression-based subtypes
identified by a consensus clustering algorithm: proneural
(N= 53), neural (N=26), classical (N= 38), and mesenchy-
mal (N=56) [15]. Three datasets generated from these
data were used for analysis: (1) a unified dataset with infor-
mation on 11,861 genes after merging the gene expression
data from Affymetrix Human Exon 1.0 ST GeneChips,
Affymetrix HT-HG-U133A GeneChips and custom
designed Agilent arrays as described in Verhaak et al. [15];
(2) a dataset including only the 840 genes selected using
SAM [16], and ClaNC [17] methods as the intrinsic GB
subtype classifier by Verhaak et al. [15] (i.e. Verhaak data-
set) and (3) a validation dataset where gene expression
array information on 176 individuals was integrated from
three studies, Beroukhim et al. [18], Phillips et al. [19] and
Sun et al. [20], using the Affymetrix HG-U133A or HG-
U133plus2 GeneChip platforms.
Breast cancer datasets
The Netherlands Cancer Institute (NKI-295) oligo-
nucleotide microarrays breast cancer dataset was used
for analysis[21]. Breast cancer subtypes were assigned
using consensus clustering based on the intrinsic gene
list of 979 genes found in four previous microarray stud-
ies as reported by Parker et al. [22-26]. Data on 172 sam-
ples was available, these were further separated into 91
training samples (basal-like (N= 29), HER2 (N= 10), lu-
minal A (N= 21) and luminal B (N= 31)) and 81 valid-
ation samples (basal-like (N= 18), HER2 (N= 11),
luminal A (N= 20) and luminal B (N= 32)).
Ovarian cancer datasets
Gene expression data from Affymetrix U133 plus 2.0 array
platform as reported by Tothill et al. [27] was utilized in
the analysis. Optimal consensus k-means clustering using
285 annotated serous and endometrioid ovarian cancer
samples identified six novel molecular subtypes (C1-C6);
C1-serous with low malignant potential, C2- high grade
ovarian cancer with a high immune signature, C3- low ma-
lignant potential, C4- high grade ovarian cancer with low
stromal response, C5-high grade ovarian cancer, mesen-
chymal, low immune signature and C6-low grade endome-
trioid. The vast majority of high grade serous and
endometrioid ovarian cancer samples (N=215) segregatedwith four of the high grade clustering predictions generat-
ing an intrinsic gene classifier that included 2,107 genes
identified using SAM[15] in a one-versus-rest fashion [16].
The ovarian dataset was further separated into 107 train-
ing samples: C1 (N=41), C2 (N=25), C4 (N=23) and C5
(N=18) and 108 validation samples: C1 (N=42), C2
(N=25), C4 (N=23) and C5 (N=18).
Additional methods
Fisher’s exact tests were carried out to assess perform-
ance of SRF after 50, 100 and 500 runs based on the true
positive rates of subtypes within GB, BC and OC data.
Non-significant Fisher’s exact p-values (0.9984, 0.9999
and 0.4057) for GB, BC and OC, respectively) demon-
strate comparability among the three SRF runs (add-
itional file 1: Tables S1, S2, S3, S4, S5, S6, Additional file
1: Figures S1, S2, S3, S4). Hence, SRF after 50 runs
(SRF50) was used in each dataset to determine overall
prediction accuracy, subtype prediction accuracy and
pairwise area under the curve (AUC) as compared with
four traditional statistical methods: single run of var-
SelRF algorithm (“Single RF”), ANOVA, Top 50 ANOVA
and published gene sets. Single RF denotes a single run
of random forest variable selection method using the
varSelRF R package[12]. ANOVA involves two steps, an
ANOVA test to discover the dominant genes between
cancer subtypes and a further false discovery rate (FDR)
correction [28] to account for multiple comparisons.
Top 50 ANOVA refers to the Top 50-genes extracted
from the above ANOVA results after ranking the genes
based on the FDR corrected p-values. The published
gene sets are the “intrinsic” gene lists obtained from pub-
lished classifiers of the molecular cancer subtypes for
each cancer of interest. For the sake of comparison, each
of the five methods was evaluated using validation data-
sets originally used per each cancer’s corresponding pub-
lication. Classifiers generated from each method, SRF50,
Single RF, ANOVA, Top 50 ANOVA and published gene
sets, was used to build random forests on the validation
datasets for GB, BC and OC.
With respect to performance evaluation criteria, over-
all prediction accuracy is the ratio of all the true posi-
tives of each subtype to the total sample, whereas
subtype prediction accuracy is the ratio of the number of
true positives for each subtype to the total number of
cases of that subtype. The robustness of the prediction
accuracy was evaluated via pairwise AUC comparisons
using two composite measurements: the multi-class
AUC value (the average of all of the pairwise AUC
values) and the Area Covered by Radar Chart (ACRC)
value[29]. Finally, the SRF50 genes were further investi-
gated for biological pathway connections and functions
using Ingenuity Pathway Analysis (IPA) (www.ingenuity.
com) and were compared with the intrinsic gene lists.
Table 1 Comparison of SRF running times (50, 100 and








GB 50 95.4% (.) 36
100 96.6% (+1.2%*) 23
500 98.9% (+3.5%**) 29
BC 50 93.6% (.) 48
100 93.6% (+0%*) 50
500 95.7% (+2.1%**) 32
OC 50 92.7% (.) 189
100 94.5% (+1.8%*) 290
500 94.5% (+1.8%**) 188
*Comparison between 50 vs. 100 runs; ** Comparison between 50 vs. 500 runs.
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network that had at least five associated genes within
that network. Those hub genes were further investigated
through a literature review to gain more biological
insight into the cancer subtypes.
Results
Glioblastoma (GB) results
SRF50 on the full GB dataset found a compact set of
genes (N= 36) with high predictive accuracy (95.4%;
Table 1 GB). All of the genes selected by SRF50 were
included on the list of significant genes by ANOVA after
a FDR correction at the significance level of 0.01
(Figure 2A) and were included as part of the VerhaakFigure 2 Venn Diagrams of the overlap between the SRF50, published
breast cancer (BC) and E. & F. for ovarian cancer (OC).classifier (Figure 2B). However, the decrease in the sizes
of the relevant gene sets is substantial, ANOVA identi-
fied 9,156 genes, Verhaak identified 840, single RF identi-
fied 88, and SRF50 identified 36.
The prediction power of the five gene lists (SRF50, single
RF, Verhaak, FDR corrected ANOVA and Top 50
ANOVA) were compared for overall and subtype predic-
tion accuracies of GB subtypes using the GB validation
dataset (Table 2 GB, Table 3 GB). Of the 9,156 genes iden-
tified using ANOVA on the unified full dataset, only 8,670
genes were contained in the validation dataset. This is be-
cause data from different array platforms were merged to
make this dataset (described in detail in Verhaak et al.)
[15]. Similarly, 833 out of 840 genes were identified from
the Verhaak gene list in the validation dataset. SRF50
achieved a prediction accuracy of 80.1% on the validation
dataset. In contrast, single RF obtained a 2.3% lower pre-
diction accuracy and used twice the number of genes as
compared to SRF50. While the Verhaak gene list obtained
a 5.9% higher prediction accuracy, it required 23 times as
many genes as the SRF50 gene set. Likewise, ANOVA also
obtained a slightly higher prediction accuracy while utiliz-
ing information on 240-times the number of genes. The
Top 50 ANOVA genes generated a 2.9% lower prediction
accuracy than the SRF50 set.
With respect to subtype prediction accuracy, while sin-
gle RF achieved the highest subtype prediction accuracy
in the most undersized class (Neural, N= 30, 80.0%), it
exhibited the poorest performance in the class with the
highest sample size class (Classical, N = 50, 64.0%). How-
ever, SRF50 obtained a consistently robust performancedatasets and the ANOVA gene lists. A. & B. for GB; C. & D. for
Table 2 Overall performance comparison of 5 gene lists in














GB SRF50 36 80.1% 0.87 1.68
Single RF88 77.8% −2.3% 0.86 1.63
Verhaak
et al.
833 86.0% 5.9% 0.92 1.91
ANOVA 8670 84.1% 4.0% 0.9 1.83
Top 50
ANOVA
50 77.2% −2.9% 0.87 1.71
BC SRF50 48 84.0% 0.91 1.85
Single RF46 74.1% −9.9% 0.87 1.69
Parker
et al.
979 89.0% 5.0% 0.89 1.78
ANOVA 4976 85.2% 1.2% 0.86 1.65
Top 50
ANOVA
50 82.7% −1.3% 0.87 1.72
OC SRF50 189 89.8% 0.96 2.06
Single RF245 88.9% −0.9% 0.96 2.06
Tothill
et al.
2106 91.7% 1.9% 0.97 2.11
ANOVA 7144 90.7% 0.9% 0.97 2.09
Top 50
ANOVA
50 87.0% −2.8% 0.95 2.01
+All changes of prediction accuracy were calculated using SRF50 as the
referent; ++ Multi-class AUC values were calculated by taking average of the all
pairwise AUC values; +++ Area covered by radar chart (ACRC) [29].
Table 3 Subtype prediction accuracy of 5 gene lists in the









GB SRF50 70.0% 81.3% 73.3% 93.8%
Single RF 64.0% 77.1% 80.0% 91.7%
Verhaak
et al.
88.0% 91.7% 50.0% 100.0%
ANOVA 88.0% 91.7% 40.0% 100.0%
Top 50
ANOVA
66.0% 83.3% 73.3% 87.5%
Basal-Like
(N= 18)




BC SRF50 100.0% 63.6% 80.0% 84.4%
Single RF 88.9% 72.7% 55.0% 87.5%
Parker
et al.
100.0% 54.5% 90.0% 93.8%
ANOVA 100.0% 36.4% 85.0% 93.8%
Top 50
ANOVA
100.0% 63.6% 75.0% 84.4%
C1 (N=42) C2 (N=25) C4 (N=23) C5 (N=18)
OC SRF50 97.6% 88.0% 73.9% 94.4%
Single RF 97.6% 88.0% 78.3% 83.3%
Tothill
et al.
97.6% 88.0% 87.0% 88.9%
ANOVA 100.0% 88.0% 78.3% 88.9%
Top 50
ANOVA
95.2% 88.0% 73.9% 83.3%
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Additional file 1: Table S7; Additional file 1: Figure S1).
Moreover, SRF50 obtained superior results compared to
single RF in both the multi-class AUC comparison (0.87
vs 0.86, Table 2 GB & Additional file 1 Table S8GB) and
the Area Covered by Radar Chart (ACRC) comparison
(1.68 vs 1.63, Table 2 GB & Figure 3). Hence, SRF50 pro-
vided highly accurate results concerning both overall and
subtype prediction accuracies while identifying a com-
pact set of optimal genes for GB subtypes.
The SRF50 GB genes were further explored using IPA
for biological pathway connections and functions. Add-
itional file 1: Table S9 (GB) lists all “hub” genes by data-
set. Several of these SRF50 “hub” genes overlapped with
the “hub” genes derived from the Verhaak gene list (RB1,
PIK3R1, PDGFBB and ERK1/2) and are known to be
involved in gliomagenesis [30-33] Additional file 1:
Figures S6A & S6B).
Breast cancer results
SRF50 on the full breast cancer dataset found a compact
set of genes (N= 48) with high predictive accuracy
(93.6%; Table 1 BC). All of the genes selected by SRF50
were contained on the list of significant genes foundusing ANOVA after an FDR correction at the signifi-
cance level of 0.01 (Figure 2C). There were 15 (31.3% of
the SRF gene list) common genes between the SRF50
gene list and the list of significant genes in the Parker
et al. [22] dataset (Figure 2D). However, the decrease in
the sizes of the relevant gene sets is considerable,
ANOVA identified 4,976 genes, Parker identified 979,
single RF identified 46 and SRF50 identified 48.
The prediction power of the five gene lists (SRF50, sin-
gle RF, Parker, FDR corrected ANOVA and Top 50
ANOVA) was compared for both the overall and subtype
prediction accuracies in the breast cancer validation
dataset (Table 2 BC, Table 3 BC). SRF achieved a predic-
tion accuracy of 84.0% on the validation dataset. As a
comparison, single RF obtained a 9.9% lower prediction
accuracy with a similar number of genes. Although the
Parker gene list obtained a 5.0% higher prediction accur-
acy it required 20 times the number of genes as com-
pared to SRF50. Similarly, ANOVA obtained a 1.2%
higher prediction accuracy while requiring over 100-
times the number of genes. The Top 50 ANOVA genes
produced a 1.3% lower prediction accuracy than SRF50.
Figure 3 Radar Chart for pairwise comparison (AUC values) for the GB dataset.
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single RF achieved the highest subtype prediction accur-
acy in the least represented subtype HER2 (N= 11,
72.7%), yet it obtained the lowest prediction accuracy
among all five methods in both Basal-Like (N= 18, 88.9%
compared with 100% in all four of other methods) and
Luminal A (N= 20, 55.0%) subtypes. The SRF50 gene list
and the Top 50 ANOVA gene list achieved the second
highest subtype prediction accuracy of the underrepre-
sented subtype (HER2, N= 11, 63.6%) in contrast to
54.5% using the Parker et al. gene list and 36.4% from
the overall ANOVA gene list(Table 3 BC, Additional file
1: Table S10 & Additional file 1: Figure S7). Furthermore,
SRF50 achieved the best results when compared with all
four of the other traditional methods in both the multi-
class AUC comparison (Table 2 BC & Additional file 1:
Table S8 BC) and the ACRC comparison (Table 2 BC &
Figure 4). Thus, SRF50 provided highly accurate results
for both overall and subtype prediction accuracies while
being robust across the subtype and identifying a com-
pact set of optimal genes.
The SRF50 genes were further analyzed for biological
pathway connections and functions using IPA. These
results were compared with those using the Parker gene
list. Additional file 1: Table S9 (BC) lists all “hub” genes
by dataset. In addition, a few of these SRF50 “hub” genesoverlapped with the “hub” genes derived from the Parker
gene list (ESR1, MYC, NFkB and ERK1/2) (Additional
file 1: Figures S8A, B & C).
Ovarian cancer results
The optimal SRF50 gene set on the full ovarian cancer
dataset found a set of probes (N= 189) with high predict-
ive accuracy (92.7%; Table 1 OC), particularly for the
high grade serous and endometrioid subtypes. All of the
genes selected by SRF50 were included on the list of sig-
nificant genes found using ANOVA after an FDR correc-
tion at the significance level of 0.01 (Figure 2E) and
there were 125 (66.1% of the SRF50 gene list) common
genes between the SRF50 gene list and the Tothill gene
list [27] (Figure 2F). However, the decrease in the sizes
of the relevant gene sets is extraordinary, ANOVA iden-
tified 7,144 genes, Tothill identified 2,106, single RF
identified 245, and SRF50 identified 189.
The prediction power of the five gene lists (SRF50, sin-
gle RF, Tothill, FDR corrected ANOVA and Top 50
ANOVA) were compared in terms of their overall and
subtype prediction accuracies in the ovarian validation
dataset (Table 2 OC and Table 3 OC). SRF achieved a
prediction accuracy of 89.8% on the validation dataset.
Single RF obtained a 0.9% lower prediction accuracy with
1.2 times the number of genes as compared to SRF50.
Figure 4 Radar Chart for pairwise comparison (AUC values) for the BC dataset.
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diction accuracy it required over 11-times the number of
genes as compared to SRF50. Similarly, ANOVA obtained a
1.0% higher prediction accuracy while requiring almost 40-
times the number of genes. When comparing the subtype
prediction accuracy using the validation dataset, the SRF50
gene list yielded the highest accuracy of the under sampled
subtype (C5, N=18, 94.4%) compared with 88.9% using the
Tothill et al. gene list and 88.9% from the ANOVA gene list
(Table 3 OC, Additional file 1 Table S11 & Additional file 1:
Figure S9). Single RF and Top 50 ANOVA yielded the low-
est subtype prediction accuracy, 83.3%, in the least sampled
class (C5, N=18). SRF50 achieved the same performance
level through both the multi-class AUC comparison (Table 2
OC& Additional file 1: Table S8 OC) and the ACRC com-
parison (Table 2 OC & Figure 5). Therefore, SRF50 pro-
vided highly accurate results while identifying a compact set
of optimal genes in terms of overall and subtype prediction
accuracies.
The SRF50 genes were further analyzed for biological
pathway connections and functions using IPA. These results
were compared with those using the Tothill gene list. Add-
itional file 1 Table S10 (OC) shows all “hub” genes by data-
set. A number of these SRF50 “hub” genes overlapped with
the “hub” genes derived from the Tothill gene list (Akt,FN1, NFkB, PDGFBB and ERK1/2) (Additional file 1
Figures S10A, B, C & D).
Discussion
An expanded random forest algorithm, Splitting Random
Forest (SRF), was developed to discover the most compact
set of genes that can distinguish between multiple groups of
individuals with known cancer molecular subtypes (glio-
blastoma, breast and ovarian). The maximum accuracy
rates of the optimal gene sets chosen from three training
datasets for three types of cancer were determined using
SRF with 50 runs (SRF50). The accuracy rates were similar
to those derived from using the intrinsic gene lists from
published molecular classifiers for each respective cancer.
All three intrinsic gene lists were generated with analysis
methods that are vulnerable to selection bias, prone to false
positives and costly in terms of time and resources. Alterna-
tively, SRF discovered small yet efficient sets of genes (less
than 40 genes for GB and less than 50 genes for BC) that
robustly distinguish between cancer subtypes and were vali-
dated in independent datasets. SRF was able to extract strik-
ingly fewer genes in contrast to ANOVA or published gene
lists for the three cancers studied. These results reveal that
the SRF algorithm can identify a compact set of genes that
robustly classifies cancer subtypes without requiring
Figure 5 Radar Chart for pairwise comparison (AUC values) for the OC dataset.
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a multiple comparison correction is not needed when using
SRF since the SRF method, by definition, prioritizes genes
by importance and removes genes from the list based on
the combination of a minimum build-in OOB error rate
and an outer test-train prediction validation to avoid poten-
tial false positives and false negatives. The 2-fold equal split
maintains robustness of the prediction accuracy and
reduces the computational complexity while focusing on a
compact set of genes.
The optimal SRF50 gene lists are efficient classifiers for
GB, breast cancer and ovarian cancer subtypes, given that
the classification prediction rates are roughly comparable
with those from the published gene lists (80.1%-86.0% for
GB, 84.0%- 89.0% for breast cancer and 89.8%-91.7% for
ovarian cancer with those from ANOVA in the middle of
the ranges) upon validation using the corresponding valid-
ation datasets from these publications. In terms of achieving
optimal compact sets of classifiers with sound prediction
accuracies, SRF50 achieved higher prediction accuracies
than the corresponding single RF results (80.1% vs 77.8%
for GB; 84.0% vs 74.1% for BC; 89.8% vs 88.9% for OC).
Meanwhile, SRF50 achieved consistently higher predictionaccuracies than Top 50 ANOVA genes for all three of the
datasets (80.1% vs 77.2% for GB; 84.0% vs 82.7% for BC;
89.8% vs 87.0% for OC). Hence, the prediction accuracy for
SRF is high regardless of sample size while utilizing infor-
mation from 10–200 fold fewer genes than published classi-
fiers. From the multi-class AUC values and the ACRC
results, SRF50 outperformed or was equivalent to the single
RF and the Top 50 ANOVA results in the GB and BC data-
sets. SRF50 achieved the same performance as single RF
and outperformed the Top 50 ANOVA method in the ovar-
ian cancer dataset. While the choice of using the Top 50
ANOVA genes may seem arbitrary and may not necessarily
represent the most compact gene classifier [11]. FDR cor-
rected ANOVA generates a long list of significant genes
based on the traditionally accepted significance level of 0.05
and these longer lists are not practically useful for diagnos-
tic purposes in clinical practice. Overall, SRF50 led to stable
and robust prediction accuracies in terms of the overall and
subtype prediction accuracies and exhibited a roughly simi-
lar range when compared to the published classifiers that
distinguish the known molecular subtypes.
SRF provides a nested-loop validation to derive the op-
timal classifiers based on the maximum prediction
Table 4 Biological functions identified from IPA using
overlapping hub gene lists of SRF 50 and the published








tumor morphology, nervous system
development and function
BC ESR1,NFkB developmental disorder, reproductive system
disease, cellular growth and proliferation;
MYC cancer, infection mechanism, gene expression
and tumor morphology
ERK1/2 molecular transport, protein trafficking and cell
cycle
OC Akt antigen presentation, cell-to-cell signaling and
interaction, cellular growth and proliferation
FN1 tissue disorders, genetic disorder and cellular
assembly and organization
NFkB embryonic development and organismal
development
PDGFBB cardiac damage, organismal injury and
abnormalities
ERK1/2 cell morphology, connective tissue development
and function
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varselRF would not achieve. The RF algorithm by defin-
ition has a built-in inner validation and the splitting test-
train technique of SRF adds an additional outer valid-
ation to the algorithm. SRF randomly splits the data X
times and then generates N tress for each split on the
training dataset, and tests each result in its own training
set and the optimal classifier is chosen from the results
from these training sets; on the other hand RF using var-
SelRF would first generate X*N trees and then calculate
the optimal classifier. Also, the variable importance
measurement (VIM) is the average of all trees (X*N) for
RF using varSelRF while for SRF the VIM is calculated
based on the training dataset only which is independent
of the testing dataset for any split.
The Random Forest algorithm is able to deal with large
scale data when the number of variables is much larger
than the number of observations (“big p small n prob-
lem”) without assuming complex models or explicitly
testing all possible interactions. RF is not limited by the
total number of prediction classes. RF returns measures
of variable importance, which reflects the total decrease
in node impurities from splitting on the specific gene,
averaged over all trees. This allows for the prioritization
of genes from each RF run for classification of groups, i.
e. optimal gene lists. However, a single run of RF using
varSelRF might identify multiple solutions based on the
build-in OOB. Hence, the SRF algorithm, takes advan-
tage of randomly splitting the original samples propor-
tionally to the size of multiple phenotypes at multiple
running times and deriving the prediction rate from one
half of the data (testing dataset) based on the first half of
the data (training dataset). This approach allows for an
outer validation combined with the inner validation
based on OOB from the varSelRF algorithm. This test-
train method has become a standard statistical technique
used for discovery and validation of new molecular clas-
sifiers. Future work may involve applying the random
splitting test-train technique to other filter, wrapper or
ensemble feature selection algorithms to potentially in-
crease computational efficiency and accuracy as well as
incorporating known biological and clinical factors into
the algorithm. Other variable measurements, such as a
minimum depth that assesses the productiveness of a
variable by its depth relative to the root node of a tree,
could also be implemented as an alternative in this set-
ting for regularizing forests[34]. In addition, SRF could
be easily extended to integrate multiple different types of
high-dimensional heterogeneous “omic” data in order to
gain a systems biology view of cancer subtypes. SRF
could also be used as a useful means to validate sub sets
of accurate predictors across independent studies [1].
In order to compare the prioritized gene lists from the
SRF algorithm with those from the published gene setsin terms of gaining better biological insight, we further
investigated “hub” genes with IPA. These “hub” genes
may be potential key masters of the signaling or func-
tional pathways for these cancers (Table 4 &Additional
file 1 Table S9). The common hub genes between the
SRF 50 and Verhaak GB gene lists were RB1, PIK3R1,
PDGFBB and ERK1/2. Via IPA, RB1 and PIK3R1 were
associated with cell morphology, hematological system
development and function; and PDGFBB and ERK1/2
were associated with tumor morphology, nervous system
development and function, tissue morphology. The com-
mon hub genes between the SRF 50 and Parker breast
cancer gene lists were ESR1, MYC, NFkB and ERK1/2.
Via IPA, ESR1 and NFkB were linked to developmental
disorder, reproductive system disease, cellular growth
and proliferation; MYC was linked to cancer, infection
mechanism, gene expression and tumor morphology;
and ERK1/2 was linked to molecular transport, protein
trafficking and cell cycle. The overlapping hub genes be-
tween the SRF 50 and Tothill gene lists were Akt, FN1,
NFkB, PDGFBB and ERK1/2. Via IPA, Akt was asso-
ciated with antigen presentation, cell-to-cell signaling
and interaction, cellular growth and proliferation; FN1
with connective tissue disorders, genetic disorder and
cellular assembly and organization; and NFkB with em-
bryonic development and organismal development.
PDGFBB with cardiac damage, organismal injury and ab-
normalities; and ERK1/2 was associated with cell morph-
ology, connective tissue development and function. The
“hub” genes discovered by SRF that overlap the “hub”
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to be fundamental for tumorgenesis and cancer develop-
ment in general. Hence, the derived SRF gene lists can
help to elucidate complex cancer systems. The non-
overlapping “hub” genes could also be potential targets
for improved cancer diagnosis and treatment.Conclusions
In conclusion, the SRF algorithm proves to be an effective
and promising tool to identify compact sets of genes that
robustly distinguish between different classes of indivi-
duals. This procedure does not require any pre-filtering
and/or pre-selection procedures thus reducing the poten-
tial for bias and/or spurious findings. In addition, applica-
tion of the SRF algorithm to the three types of cancer data
showed that relatively small set of genes as identified by
SRF had similar classification rates as compared to pub-
lished classifiers. These small gene set classifiers can be
investigated further as potential molecular diagnostics
which could lead to tailored cancer treatments.Additional file
Additional file 1: Table S1 Comparison of performance by subtype of
SRF50, 100 and 500 runs in the GB full dataset. Table S2 Comparison of
performance by subtype of SRF50, 100 and 500 runs in the breast cancer
training dataset. Table S3 Comparison of performance by subtype of
SRF50, 100 and 500 runs in the ovarian cancer training dataset. Table S4
Comparison of the gene lists from SRF50, 100 and 500 runs for GB. Table
S5 Comparisons of the gene lists from SRF50, 100 and 500 runs for breast
cancer. Table S6 Comparisons of the gene lists from SRF50, 100 and 500
runs for ovarian cancer. Table S7 Comparison of performance by subtype
of five gene lists in the GB validation dataset. Table S8 Pairwise AUC
comparison between subtypes of five gene lists in the GB, BC and OC
validation dataset. Table S9 Hub genes in the top networks from IPA
analysis for the SRF50 and published gene lists for GB, breast cancer (BC)
and ovarian cancer (OC). Table S10 Comparison of performance by
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Top 50 ANOVA. Figure S6 A and B: IPA network plots showing the
overlap in the hub genes for the SRF50 gene list and the Verhaak list
(grey lines denote the SRF50 gene list and green lines denote the
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